DDInter201 DDInter698
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.[A192834,A192888,A192837,A192891,A192894] In 2004, bevacizumab (Avastin) gained FDA approval for specific types of cancer, and became the first antiangiogenic agent introduced to the market.[A193272,A193275] It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and neutralizing VEGF-A.[A192888,A192939] Bevacizumab is generally indicated for use in combination with different chemotherapy regimens which are specific to the type, severity
Etidronic acid is a first generation bisphosphonate similar to [clodronic acid] and [tiludronic acid]. These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. Etidronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate [zoledronic acid], [ibandronic acid], [minodronic acid], and [risedronic acid]. Etidronic acid was granted FDA approval on 1 September 1977.
Bevacizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risedronic acid
Risedronic acid {u} (Compound) resembles {v} (Compound) Etidronic acid
Bevacizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risedronic acid
Risedronic acid {u} (Compound) resembles {v} (Compound) Ibandronate
Ibandronate {u} (Compound) resembles {v} (Compound) Etidronic acid
Bevacizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibandronate
Ibandronate {u} (Compound) resembles {v} (Compound) Risedronic acid
Risedronic acid {u} (Compound) resembles {v} (Compound) Etidronic acid
Bevacizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Radium Ra 223 dichloride
Radium Ra 223 dichloride {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Etidronic acid
Bevacizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pamidronic acid
Pamidronic acid {u} (Compound) resembles {v} (Compound) Clodronate
Clodronate {u} (Compound) resembles {v} (Compound) Etidronic acid
Bevacizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tiludronic acid
Tiludronic acid {u} (Compound) treats {v} (Disease) Paget's disease of bone
Paget's disease of bone {u} (Disease) is treated by {v} (Compound) Etidronic acid
Bevacizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) downregulates {v} (Gene) RAN
RAN {u} (Gene) is downregulated by {v} (Compound) Etidronic acid
Bevacizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tiludronic acid
Tiludronic acid {u} (Compound) binds {v} (Gene) ATP6V1A
ATP6V1A {u} (Gene) is bound by {v} (Compound) Etidronic acid
Bevacizumab {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Deferiprone {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Etidronic acid
Bevacizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tiludronic acid
Tiludronic acid {u} (Compound) is included by {v} (Pharmacologic Class) Diphosphonates
Diphosphonates {u} (Pharmacologic Class) includes {v} (Compound) Etidronic acid
Bevacizumab may cause a moderate interaction that could exacerbate diseases when taken with Risedronic acid and Risedronic acid (Compound) resembles Etidronic acid (Compound)
Bevacizumab may cause a moderate interaction that could exacerbate diseases when taken with Risedronic acid and Risedronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate (Compound) resembles Etidronic acid (Compound)
Bevacizumab may cause a moderate interaction that could exacerbate diseases when taken with Ibandronate and Ibandronate (Compound) resembles Risedronic acid (Compound) and Risedronic acid (Compound) resembles Etidronic acid (Compound)
Bevacizumab may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride and Radium Ra 223 dichloride (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Etidronic acid (Compound)
Bevacizumab may cause a moderate interaction that could exacerbate diseases when taken with Pamidronic acid and Pamidronic acid (Compound) resembles Clodronate (Compound) and Clodronate (Compound) resembles Etidronic acid (Compound)
Bevacizumab may cause a moderate interaction that could exacerbate diseases when taken with Tiludronic acid and Tiludronic acid (Compound) treats Paget's disease of bone (Disease) and Paget's disease of bone (Disease) is treated by Etidronic acid (Compound)
Bevacizumab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) downregulates RAN (Gene) and RAN (Gene) is downregulated by Etidronic acid (Compound)
Bevacizumab may cause a moderate interaction that could exacerbate diseases when taken with Tiludronic acid and Tiludronic acid (Compound) binds ATP6V1A (Gene) and ATP6V1A (Gene) is bound by Etidronic acid (Compound)
Bevacizumab may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Etidronic acid (Compound)
Bevacizumab may cause a moderate interaction that could exacerbate diseases when taken with Tiludronic acid and Tiludronic acid (Compound) is included by Diphosphonates (Pharmacologic Class) and Diphosphonates (Pharmacologic Class) includes Etidronic acid (Compound)